**Table 4. Systemic review of antiplatelets regiment for stent in treatment of intracerebral aneurysms**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Study | Case No. | Antiplatelets | Procedures | In stent thrombosis | Early TE1 |
| Hwang 2013[7] | 116 | Aspirin + Clopidogrel | SACE | 1.72% | 5.17% |
| Kono 2013[24] | 36 | Aspirin + Clopidogrel | SACE | 0% | 0% |
|  | 4 | Aspirin + Clopidogrel + Cilostazol | Y-stent coiling | 0% | 50% |
| Hwang 2014[25] | 395 | Aspirin + Clopidogrel | SACE | 4.05% | 7.59% |
| Starke 2014[26] | 120 | Aspirin + Clopidogrel | SACE | 4.17% | 7.50% |
| Matsumoto 2014[27] | 18 | Aspirin + Clopidogrel | SACE | N/A | 22.22% |
|  | 25 | Aspirin + Cilostazol | SACE | N/A | 20.00% |
| Takigawa 2014[12] | 43 | Aspirin + Clopidogrel | SACE | 6.98% | 6.98% |
| Hong 2014[8] | 753 | Aspirin + Clopidogrel | SACE | N/A | 17.6% |
| Song 2015[28] | 125 | Aspirin + Clopidogrel | SACE | 0% | 1.6% |
| Matsumoto 2015[29] | 51 | Aspirin + Clopidogrel | SACE | 0% | 13.73% |
|  | 28 | Aspirin + Clopidogrel + Cilostazol | SACE | 0% | 0% |
| Ha 2016[30] | 96 | Clopidogrel | Endovascular procedure 2 | 0% | 0% |
|  | 98 | Prasugrel | Endovascular procedure 2 | 0% | 0% |
| Kim 2016[37] | 246 | Aspirin + Clopidogrel | SACE | N/A | 10.16% |
|  | 124 | DRT 3 | SACE |  | 2.46% |
| Bechan 2016[9] | 46 | Aspirin + Clopidogrel | SACE | N/A | 4.35% |
| Park 2016[31] | 105 | Aspirin + Clopidogrel | SACE | 0% | 0.95% |
|  | 229 | Aspirin + Clopidogrel 4 | SACE | 4.8% | 15.81% |
|  | 102 | Aspirin + Clopidogrel + cilostazol or ticlopidine | SACE | 3.9% | 6.86% |
| Song 2017[32] | 99 | Aspirin + Clopidogrel | SACE | 4.04% | 14.14% |
| Choi 2017[34] | 90 | Aspirin + Clopidogrel | SACE | 3.33% | 6.67% |
|  | 207 | Prasugrel | SACE | 0.48% | 0.97% |
| Sedat 2017[33] | 100 | Aspirin + Clopidogrel | SACE | 3% | 20% |
|  | 100 | Aspirin + Prasugrel | SACE | 0% | 12% |
| Kim 2018[35] | 507 | Aspirin + Clopidogrel | SACE | 0.19% | 1.38% |
| Soize 2019[36] | 40 | Aspirin + Clopidogrel | Flow diverter | 12.5% | 20% |
|  | 40 | Aspirin + Ticagrelor | Flow diverter | 5% | 7.5% |
| Hanel 2014[23] | 18 | Ticagrelor | All stent procedure 5 | 0% | 0% |
| Narata 2019[21] | 154 | Aspirin + Ticagrelor | Flow diverter and SACE | N/A | 1.9% |
| Current study | **113** | **Aspirin + Clopidogrel** | **Stent-assisted coiling** | **1.77%** | **2.65%** |
|  | **40** | **Aspirin + Ticagrelor** | **Stent-assisted coiling** | **0%** | **0%** |

SACE: stent assisted coiling embolization; N/A: no mention in the article

1. Early TE: thromboembolic events < 3 months or under dual antiplatelets (include in stent thrombosis)
2. Include SACE, flow diverter, double catheters, etc.
3. DRT: drug resistant therapy, no detail in the article
4. Group for Clopidogrel resistance
5. Include carotid stent, intra-, extra-cranial stents, and flow diverter